N/A N=226 Barbed Suture for Hysterotomy Closure During Cesarean Section
Hysterotomy
Primary: Quantitative Blood Loss — 641.8; 596.5 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Hysterectomy by Transabdominal Laparoscopy or NOTES
Uterine Diseases
Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221
N/A N=60 Histerectomy Vs Partial Myometrial Resection for Placenta Accreta Spectrum
Placenta Accreta
Primary: Feasibility: Proportion of Eligible Patients Who Agree to Participate in the Study. — 60 Participants
N/A N=96 Scalpel vs Diathermy in Repeat Cesarean Delivery
Complications; Cesarean Section
Primary: Incision Time . — 271.5; 188.17 Seconds — p=<0.001
Phase 4 N=40 Harmonic ACE®+7 Shears in Laparoscopic Hysterectomy
Benign Disease Where Total Hysterectomy is Indicated
Primary: Percentage of Subjects Achieving Hemostasis at the Named Vessel/Pedicle (UA or UP) on the Left Side. — 97.5 percentage of participants
N/A N=52 Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy
Benign Uterine Disease
Primary: The Primary Endpoint of This Study is Time Difference Between Cauterizing One Side of the Uterine Attachments, From the Round Ligament to the Uterine Artery on One Side…
N/A N=251 Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption
Placenta, Retained · Postpartum Hemorrhage
Primary: Placental Retention Rate — 26; 8; 24 participants — p=0.05
N/A N=50 Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer
Endometrial Cancer
Primary: Health Related Quality of Life (HRQoL) — 0.34; 0.30; 0.66; 0.48 scores on a scale — p=0.011
N/A N=282 Single or Double-layer Uterine Closure Techniques
Uterine Scar · Cesarean Section Complications · Cesarean Section; Dehiscence
Primary: Number of Participants With Niche Visualized by Saline Infusion Sonography — 40; 53; 25; 23 Participants — p=0.05
N/A N=3 Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata
Uterine Fibroids · Leiomyoma · Menorrhagia
Primary: Number of Adverse Events — 1 Participants
N/A N=79 Improving Cesarean Section Experience Through Hypnotherapy
Cesarean Section · Pain · Anxiety
Primary: Wellbeing Measured Using a Comfort Scale — 6.7; 8.0 units on a scale
N/A N=49 Vaginally Assisted Laparoscopic Hysteropexy Versus Vaginal Hysterectomy
Pelvic Organ Prolapse
Primary: Number of Participants With Recurrence of Pelvic Organ Prolapse — 0; 0 Participants
N/A N=168 Short Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure
Cesarean Section Complications
Primary: Cesarean Scar Defect in the Uterine Incisional Line — 12; 39 participants — p=0.0001
Phase 4 N=87 TAP vs Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Hysterectomy
Acute Pain
Primary: Total Opioid Use for Pain Control — 20.8; 25.0 mg Morphine equivalents
N/A N=22 Surgicel Snow in Gynecological Surgery
Laparoscopic Hysterectomy
Primary: Change in Bleeding at Specified Time Intervals — 485.7; 199.1 seconds
N/A N=200 Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage
Postpartum Hemorrhage · Uterine Atony
Primary: Blood Loss — 616; 418; 141; 106 cc
N/A N=74 HOME Study: Hysteroscopic Office Myomectomy Evaluation
Uterine Fibroids · Polyps
Primary: Percent Reduction in Target Pathology Volume — 96.9; 99.9 percentage of fibriods/polyps
N/A N=97 Laparoscopic Enclosed Morcellation; Electromechanic Morcellation vs Vaginal Removal
Myoma
Primary: Operation Time — 146.1; 124.6 seconds
N/A N=100 Clinical Trial Comparing Conventional and Robot-assisted(Da Vinci®)Laparoscopic Interventions for Hysterectomy
Laparoscopic Technique no Switch to Open · Duration of Surgery · Intraoperative Complications
Primary: Duration of Surgery — 75; 106 minutes
N/A N=168 Long Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure
Cesarean Section; Complications · Placenta Previa · Placenta Accreta
Primary: Placenta Previa — 18; 17; 0; 3 Participants
Early Phase 1 N=103 Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Cervical Cancer · Uterine Endometrial Cancer · Ovarian Cancer
Primary: Hospital Stay — 3.0; 3.0 Days — p=0.36
N/A N=40 Opportunistic Salpingectomy for Permanent Sterilization at the Time of Cesarean Delivery
Contraception
Primary: Mean Difference Between Pre and Postoperative Hemoglobin (g/dl) — 1.4; 1.8 g/dL — p=0.08
N/A N=75 Ultrasound-guided Transversus Abdominis Plane Block After Hysterectomy
Post Operative Pain
Primary: Morphine Consumption — 38.4; 38.6; 42.6 mg
N/A N=32 Transcervical Balloon Compared to Osmotic Dilators Prior to Surgical Abortion
Abortion, Second Trimester
Primary: Procedure Time — 22.4; 22.6 minutes
N/A N=84 Urinary Retention After Total Laparoscopic Hysterectomy With Immediate Foley Catheter Removal Versus Backfill Void Trial
Urinary Retention · Voiding Disorders
Primary: Number of Participants With Void Trial Failure Rate — 7; 11 Participants
Phase 3 N=236 Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia
Menorrhagia
Primary: HRQoL (Health Related Quality of Life) — 0.08; 0.10 points on a scale
Phase 4 N=106 Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System
Menorrhagia
Primary: Success (Reduction in Menstruation to Normal Levels) — 59 Participants — p=.271
Phase 3 N=15 Intraoperative Trocar Slippage Study
Trocar Slippage
Primary: Trocar Slippages With LaproStop — 1; 2; 3 Participants
N/A N=147 Sonography Guided Transcervical Ablation of Uterine Fibroids
Menorrhagia
Primary: Percentage of Subjects With ≥ 50% Reduction in Menstrual Blood Loss as Assessed by Pictorial Blood Loss Assessment Chart (PBAC) — 64.8 percentage of participants
Phase 4 N=18 Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
Myomectomy; Surgical Blood Loss
Primary: Surgical Blood Loss — 761; 691 ml